当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Diagnosis Cell Lung Cancer with Bone Metastases: An Over View

Ping Wang

Rarely have the characteristics and prognostic factors of SCLC patients with bone metastases at first diagnosis been discussed. The purpose of this study was to examine these patients' prognostic factors and create a survival scoring system to support clinical treatment decisions. Retrospective review was conducted on the records of 102 SCLC patients with bone metastasis at the time of diagnosis who were seen at our hospital between May 2010 and May 2015. Potential clinical survival predictors were evaluated using the log-rank test and multivariate Cox regression analysis. Based on the hazard ratios of significant independent prognostic factors, a scoring system was developed. The spine was the most common location for bone metastases (64.7%), and 26 patients (25.6%) had just one bone metastasis. The 2-year survival rate was 10.3%, and the median survival time was 10.4 months. Independently, age, the number of bone metastases, and the occurrence of extraosseous distant metastases had a significant impact on overall survival. Patients were placed into one of three groups based on their scores. The three groups had median survival times of 6.4 months, 8.5 months, and 12.4 months, respectively, and 2-year survival rates of 0%, 2.9%, and 19.3% (p=0.000). Radiation to the bone (22.5%) and spinal cord compression (11.8%) were the most common skeletal-related events (SREs) in 26 patients (25.5%). At the time of diagnosis, this study includes preliminary clinical data from SCLC patients with bone metastases

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。